These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30629340)

  • 1. Dynamics in HIV-DNA levels over time in HIV controllers.
    Avettand-Fenoel V; Bayan T; Gardiennet E; Boufassa F; Lopez P; Lecuroux C; Noel N; Trémeaux P; Monceaux V; Autran B; Meyer L; Saez-Cirion A; Lambotte O; Rouzioux C;
    J Int AIDS Soc; 2019 Jan; 22(1):e25221. PubMed ID: 30629340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood.
    Hocini H; Bonnabau H; Lacabaratz C; Lefebvre C; Tisserand P; Foucat E; Lelièvre JD; Lambotte O; Saez-Cirion A; Versmisse P; Thiébaut R; Lévy Y
    J Virol; 2019 May; 93(10):. PubMed ID: 30814287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case report of HIV-1 superinfection in an HIV controller leading to loss of viremia control: a retrospective of 10 years of follow-up.
    Caetano DG; Côrtes FH; Bello G; de Azevedo SSD; Hoagland B; Villela LM; Grinsztejn B; Veloso VG; Guimarães ML; Morgado MG
    BMC Infect Dis; 2019 Jul; 19(1):588. PubMed ID: 31277590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.
    Ruggiero A; De Spiegelaere W; Cozzi-Lepri A; Kiselinova M; Pollakis G; Beloukas A; Vandekerckhove L; Strain M; Richman D; Phillips A; Geretti AM;
    EBioMedicine; 2015 Sep; 2(9):1153-9. PubMed ID: 26498496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
    Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers.
    Lécuroux C; Sáez-Cirión A; Girault I; Versmisse P; Boufassa F; Avettand-Fenoël V; Rouzioux C; Meyer L; Pancino G; Lambotte O; Sinet M; Venet A
    J Virol; 2014 Jan; 88(1):176-87. PubMed ID: 24131719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years.
    Poizot-Martin I; Faucher O; Obry-Roguet V; Nicolino-Brunet C; Ronot-Bregigeon S; Dignat-George F; Tamalet C
    J Clin Virol; 2013 Aug; 57(4):351-5. PubMed ID: 23664725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control.
    Kloverpris HN; Stryhn A; Harndahl M; van der Stok M; Payne RP; Matthews PC; Chen F; Riddell L; Walker BD; Ndung'u T; Buus S; Goulder P
    J Virol; 2012 Jan; 86(2):919-29. PubMed ID: 22090105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.
    Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR
    J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Progression in HIV-1-Infected Viremic Controllers.
    Groves KC; Bibby DF; Clark DA; Isaksen A; Deayton JR; Anderson J; Orkin C; Stagg AJ; McKnight A
    J Acquir Immune Defic Syndr; 2012 Dec; 61(4):407-16. PubMed ID: 22902723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy.
    Gálvez C; Grau-Expósito J; Urrea V; Clotet B; Falcó V; Buzón MJ; Martinez-Picado J
    mBio; 2021 Dec; 12(6):e0307821. PubMed ID: 34844430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
    Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.
    Emu B; Sinclair E; Hatano H; Ferre A; Shacklett B; Martin JN; McCune JM; Deeks SG
    J Virol; 2008 Jun; 82(11):5398-407. PubMed ID: 18353945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
    Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
    J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HLA selection pressure on HIV fitness at a population level in Mexico and Barbados.
    Juarez-Molina CI; Payne R; Soto-Nava M; Avila-Rios S; Valenzuela-Ponce H; Adland E; Leitman E; Brener J; Muenchhoff M; Branch S; Landis C; Reyes-Teran G; Goulder P
    J Virol; 2014 Sep; 88(18):10392-8. PubMed ID: 25008926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of CDKN1A/p21 in HIV-1 controllers is correlated with upregulation of ZC3H12A/MCPIP1.
    de Azevedo SSD; Ribeiro-Alves M; Côrtes FH; Delatorre E; Spangenberg L; Naya H; Seito LN; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Souza TML; Bello G
    Retrovirology; 2020 Jul; 17(1):18. PubMed ID: 32615986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.
    Sáez-Cirión A; Bacchus C; Hocqueloux L; Avettand-Fenoel V; Girault I; Lecuroux C; Potard V; Versmisse P; Melard A; Prazuck T; Descours B; Guergnon J; Viard JP; Boufassa F; Lambotte O; Goujard C; Meyer L; Costagliola D; Venet A; Pancino G; Autran B; Rouzioux C;
    PLoS Pathog; 2013 Mar; 9(3):e1003211. PubMed ID: 23516360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.